Rajakariar Kevin, Andrianopoulos Nick, Gayed Daniel, Liang Danlu, Backhouse Brendan, Ajani Andrew E, Duffy Stephen J, Brennan Angela, Roberts Louise, Reid Christopher M, Oqueli Ernesto, Clark David, Freeman Melanie
Department of Cardiology, Eastern Health, Melbourne, Victoria, Australia.
Centre of Cardiovascular Research and Education in Therapeutics (CCRE), School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Intern Med J. 2023 Aug;53(8):1376-1382. doi: 10.1111/imj.15828. Epub 2022 Sep 14.
Previous large multi-centre randomised controlled trials have not provided clear benefit with routine intracoronary thrombus aspiration (TA) as an adjunct to primary percutaneous coronary intervention (PCI) in patients with ST-elevation myocardial infarction (STEMI).
To determine whether there is a difference in outcomes with the use of manual TA prior to PCI, compared with PCI alone in a cohort of patients with STEMI.
We analysed data from 6270 consecutive patients undergoing primary PCI for STEMI prospectively enrolled in the Melbourne Interventional Group registry between 2007 and 2018. Multivariable analysis was performed to determine predictors of 30-day major adverse cardiovascular and cerebrovascular events (MACCE) and long-term mortality.
We compared 1621 (26%) patients undergoing primary PCI with TA to 4649 (74%) patients undergoing PCI alone. Male gender (81% vs 78%; P < 0.01), younger age (61 vs 63 years; P = 0.03), GP-IIb/IIIa use (76% vs 58%, P < 0.01), and current smoking (40% vs 36%; P < 0.01) were more common in the TA group. TA was more likely to be used in patients with complex lesions (83% vs 66%; P < 0.01) with TIMI 0 flow (77% vs 56%; P < 0.01). No significant difference in post-procedural TIMI flow, stroke, 30-day mortality, or long-term mortality were identified. Multivariable analysis demonstrated a reduction in 30-day MACCE (hazard ratio (HR) 0.75; confidence interval (CI) 0.63-0.89; P < 0.01) in the TA group, but was not associated with long-term mortality (HR 0.98; CI 0.85-1.1; P = 0.73).
The use of TA in patients undergoing primary PCI for STEMI was not associated with improved short or long-term mortality when compared with PCI alone.
既往大型多中心随机对照试验并未明确显示,对于ST段抬高型心肌梗死(STEMI)患者,常规冠状动脉内血栓抽吸术(TA)作为直接经皮冠状动脉介入治疗(PCI)的辅助手段能带来益处。
确定在STEMI患者队列中,PCI前使用手动TA与单纯PCI相比,结局是否存在差异。
我们分析了2007年至2018年期间前瞻性纳入墨尔本介入组登记处的6270例连续接受STEMI直接PCI的患者的数据。进行多变量分析以确定30天主要不良心血管和脑血管事件(MACCE)及长期死亡率的预测因素。
我们将1621例(26%)接受PCI联合TA的患者与4649例(74%)单纯接受PCI的患者进行了比较。TA组男性比例更高(81%对78%;P<0.01)、年龄更小(61岁对63岁;P = 0.03)、使用糖蛋白IIb/IIIa抑制剂的比例更高(76%对58%,P<0.01)以及当前吸烟者比例更高(40%对36%;P<0.01)。TA更有可能用于病变复杂(83%对66%;P<0.01)且心肌梗死溶栓治疗(TIMI)血流0级的患者(77%对56%;P<0.01)。未发现术后TIMI血流、卒中、30天死亡率或长期死亡率有显著差异。多变量分析显示TA组30天MACCE降低(风险比(HR)为0.75;置信区间(CI)为0.63 - 0.89;P<0.01),但与长期死亡率无关(HR为0.98;CI为0.85 - 1.1;P = 0.73)。
与单纯PCI相比,STEMI患者直接PCI时使用TA与短期或长期死亡率改善无关。